Literature DB >> 23652051

Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis.

Bing-sheng Sun1, Jian You, Yue Li, Zhen-fa Zhang, Chang-li Wang.   

Abstract

BACKGROUND: Osteopontin (OPN) was identified as one of the leading genes that promote the metastasis of malignant tumor. However, the mechanism by which OPN mediates metastasis in non-small cell lung cancer (NSCLC) remains unknown. The aim of the study is to investigate the biological significance and the related molecular mechanism of OPN expression in lung cancer cell line.
METHODS: Lentiviral-mediated RNA interference was applied to inhibit OPN expression in metastatic human NSCLC cell line (A549). The invasion, proliferation, and metastasis were evaluated OPN-silenced in A549 cells in vitro and in vivo. The related mechanism was further investigated.
RESULTS: Interestingly, OPN knockdown significantly suppressed the invasiveness of A549 cells, but had only a minor effect on the cellular migration and proliferation. Moreover, we demonstrated that OPN knockdown significantly reduced the levels of matrix metalloproteinase (MMP)-2 and urokinase plasminogen activator (uPA), and led to an obvious inhibition of both in vitro invasion and in vivo lung metastasis of A549 cells (P < 0.001).
CONCLUSIONS: Our data demonstrate that OPN contributes to A549 cell metastasis by stimulating cell invasion, independent of cellular migration and proliferation. OPN could be a new treatment target of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652051

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  12 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  The downregulation of OPN inhibits proliferation and migration and regulate activation of Erk1/2 in ECA-109 cells.

Authors:  Song-Tao Xu; Fa-Zhang Zou; Li-Na Cai; Wan-Ling Xu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.

Authors:  M A Elbaiomy; T Akl; R Elhelaly; W El-Beshbishi; M S El Ghonemy; R Elzehery
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

4.  PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro.

Authors:  Hong-Xia Bi; Han-Bing Shi; Ting Zhang; Ge Cui
Journal:  Chin Med J (Engl)       Date:  2015-02-05       Impact factor: 2.628

5.  Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.

Authors:  Yulong Fu; Yang Zhang; Zhe Lei; Ting Liu; Tingting Cai; Anqi Wang; Wenwen Du; Yuanyuan Zeng; Jianjie Zhu; Zeyi Liu; Jian-An Huang
Journal:  J Hematol Oncol       Date:  2020-12-07       Impact factor: 17.388

6.  Functional assessment of glioma pathogenesis by in vivo multi-parametric magnetic resonance imaging and in vitro analyses.

Authors:  Nai-Wei Yao; Chen Chang; Hsiu-Ting Lin; Chen-Tung Yen; Jeou-Yuan Chen
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

7.  Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.

Authors:  Dan Li; Wang Qian; Ruo Ran Li; Jinghao Zhang; K E Li; Yanmin Wu
Journal:  Biomed Rep       Date:  2016-02-29

Review 8.  [Advances in Research of Osteopontion and Its Receptor CD44v in Tumor Invasion and Metastasis].

Authors:  Bingsheng Sun; Zhenfa Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-11

Review 9.  Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight.

Authors:  Anne-Sophie Lamort; Ioanna Giopanou; Ioannis Psallidas; Georgios T Stathopoulos
Journal:  Cells       Date:  2019-08-02       Impact factor: 6.600

10.  Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells.

Authors:  Jian Cui; Jun Wang; Chao Lin; Jixiang Liu; Wei Zuo
Journal:  Onco Targets Ther       Date:  2019-11-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.